Prevenar® (7-valent pneumococcal conjugate vaccine) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
65. Primary immunodeficiency
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01075438 (ClinicalTrials.gov) | March 2010 | 24/2/2010 | Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients | Descriptive Immunogenicity of 2 Doses of Pneumococcal 7-valent Conjugate Vaccine (Prevenar®, Wyeth Lederle) Followed by Pneumococcal Polysaccharide Vaccine (Pneumovax® Aventis Pasteur MSD) in Ataxia-telangiectasia Patients | Ataxia Telangiectasia | Biological: Prevenar® (7-valent pneumococcal conjugate vaccine);Biological: Pneumovax® (pneumococcal polysaccharide vaccine) | Sheba Medical Center | NULL | Not yet recruiting | 2 Years | 25 Years | Both | 20 | N/A | Israel |